These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 15794392)
1. Self-injection anxiety training: a treatment for patients unable to self-inject injectable medications. Mohr DC; Cox D; Merluzzi N Mult Scler; 2005 Apr; 11(2):182-5. PubMed ID: 15794392 [TBL] [Abstract][Full Text] [Related]
2. An open-label, multicenter study to evaluate the safe and effective use of the single-use autoinjector with an Avonex® prefilled syringe in multiple sclerosis subjects. Phillips JT; Fox E; Grainger W; Tuccillo D; Liu S; Deykin A BMC Neurol; 2011 Oct; 11():126. PubMed ID: 21999176 [TBL] [Abstract][Full Text] [Related]
3. Injectable medication for the treatment of multiple sclerosis: the influence of self-efficacy expectations and injection anxiety on adherence and ability to self-inject. Mohr DC; Boudewyn AC; Likosky W; Levine E; Goodkin DE Ann Behav Med; 2001; 23(2):125-32. PubMed ID: 11394554 [TBL] [Abstract][Full Text] [Related]
4. A prospective baseline versus on-treatment study assessing patient perceptions of using a smaller needle when injecting intramuscular interferon beta-1 a (Avonex). Freedman SM; Cox D; Rosebrough T J Neurosci Nurs; 2008 Dec; 40(6):350-5. PubMed ID: 19170302 [TBL] [Abstract][Full Text] [Related]
5. Injection anxiety remains a long-term barrier to medication adherence in multiple sclerosis. Turner AP; Williams RM; Sloan AP; Haselkorn JK Rehabil Psychol; 2009 Feb; 54(1):116-21. PubMed ID: 19618711 [TBL] [Abstract][Full Text] [Related]
6. Single-use autoinjector for once-weekly intramuscular injection of IFNβ-1a. Limmroth V; Gerbershagen K Expert Opin Drug Deliv; 2014 Dec; 11(12):1969-78. PubMed ID: 25255732 [TBL] [Abstract][Full Text] [Related]
7. Teaching patients to self-inject: pilot study of a treatment for injection anxiety and phobia in multiple sclerosis patients prescribed injectable medications. Mohr DC; Cox D; Epstein L; Boudewyn A J Behav Ther Exp Psychiatry; 2002 Mar; 33(1):39-47. PubMed ID: 12389798 [TBL] [Abstract][Full Text] [Related]
8. [Teaching intramuscular self-injection in patients with multiple sclerosis reaching interferon beta-1a: evaluation of a descriptive multicenter program]. Visy JM; Gentin M; Bazerque C; Presse Med; 2007 Jun; 36(6 Pt 1):841-50. PubMed ID: 17482792 [TBL] [Abstract][Full Text] [Related]
9. Adherence to therapy: using an evidence-based protocol. Moore LA; Kaufman MD; Algozzine R; Irish N; Martin M; Posey CR Rehabil Nurs; 2007; 32(6):227-32. PubMed ID: 18065143 [TBL] [Abstract][Full Text] [Related]
10. Multiple sclerosis patients treated with intramuscular IFN-β-1a autoinjector in a real-world setting: prospective evaluation of treatment persistence, adherence, quality of life and satisfaction. Hupperts R; Becker V; Friedrich J; Gobbi C; Salgado AV; Sperling B; You X Expert Opin Drug Deliv; 2015 Jan; 12(1):15-25. PubMed ID: 25430947 [TBL] [Abstract][Full Text] [Related]
11. MxA protein induction in MS patients treated with intramuscular IFNbeta-1a. Vallittu AM; Salmi AA; Erälinna JP; Neurol Sci; 2006 Feb; 26(6):438-43. PubMed ID: 16601938 [TBL] [Abstract][Full Text] [Related]
12. Weekly IM interferon beta-1a in multiple sclerosis patients over 50 years of age. Lampl C; You X; Limmroth V Eur J Neurol; 2012 Jan; 19(1):142-8. PubMed ID: 21718390 [TBL] [Abstract][Full Text] [Related]
14. Adherence to interferon β-1a therapy using an electronic self-injector in multiple sclerosis: a multicentre, single-arm, observational, phase IV study. Devonshire VA; Feinstein A; Moriarty P BMC Res Notes; 2016 Mar; 9():148. PubMed ID: 26951043 [TBL] [Abstract][Full Text] [Related]
15. Glatiramer acetate and interferon beta-1a for intramuscular administration: a study of outcomes among multiple sclerosis intent-to-treat and persistent-use cohorts. Castelli-Haley J; Oleen-Burkey MA; Lage MJ; Johnson K J Med Econ; 2010; 13(3):464-71. PubMed ID: 20662760 [TBL] [Abstract][Full Text] [Related]
16. Swiss analysis of multiple sclerosis: a multicenter, non-interventional, retrospective cohort study of disease-modifying therapies. Gobbi C; Zecca C; Linnebank M; Müller S; You X; Meier R; Borter E; Traber M Eur Neurol; 2013; 70(1-2):35-41. PubMed ID: 23689307 [TBL] [Abstract][Full Text] [Related]
17. Will new injection devices for interferon β-1a s.c. affect treatment adherence in patients with multiple sclerosis? An expert opinion in the Middle East. Deleu D; Alsharoqi I; Al Jumah MA; Al Tahan AR; Bohlega S; Dahdaleh M; Inshasi J; Khalifa A; Szólics M; Yamout BI Int J Neurosci; 2011 Apr; 121(4):171-5. PubMed ID: 21329472 [TBL] [Abstract][Full Text] [Related]
18. Frequency and magnitude of interferon β neutralizing antibodies in the evaluation of interferon β immunogenicity in patients with multiple sclerosis. Grossberg SE; Oger J; Grossberg LD; Gehchan A; Klein JP J Interferon Cytokine Res; 2011 Mar; 31(3):337-44. PubMed ID: 21226608 [TBL] [Abstract][Full Text] [Related]
19. Persistence and adherence to disease modifying drugs among patients with multiple sclerosis. Reynolds MW; Stephen R; Seaman C; Rajagopalan K Curr Med Res Opin; 2010 Mar; 26(3):663-74. PubMed ID: 20070144 [TBL] [Abstract][Full Text] [Related]
20. A randomized, multicentre, open-label, parallel-group trial of the tolerability of interferon beta-1a (Rebif) administered by autoinjection or manual injection in relapsing-remitting multiple sclerosis. Mikol D; Lopez-Bresnahan M; Taraskiewicz S; Chang P; Rangnow J; Mult Scler; 2005 Oct; 11(5):585-91. PubMed ID: 16193898 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]